Key facts
- This page summarizes RA CAPITAL MANAGEMENT, L.P.'s Form 4 filing for Kala Pharmaceuticals, Inc. (KALA).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 26 May 2022, 17:09.
RA CAPITAL MANAGEMENT, L.P. - 26 May 2022 Form 4 Insider Report for Kala Pharmaceuticals, Inc. (KALA)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- KALA
- Reported as of
- 26 May 2022
- Net transaction value
- -$365,667
- SEC form
- 4
- Accepted by SEC
- 26 May 2022, 17:09:58 UTC
- Prior SEC filing
- 25 May 2022
- Next SEC filing
- 03 Jun 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Peter Kolchinsky, Manager of RA Capital Management, L.P.
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
RA CAPITAL MANAGEMENT, L.P. filed Form 4 for Kala Pharmaceuticals, Inc. (KALA) on 26 May 2022.
Change
- Previous filing in this sequence was filed on 25 May 2022.
- Current net transaction value: -$365,667.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
KALA
transaction
Common Stock
Sale
- Transaction value
- $365,667
- Shares
- -1,005,686
- Change %
- -13%
- Price
- $0.3636
- Shares after
- 7,039,613
- Date
- 26 May 2022
- Ownership
- See Footnotes
- Footnotes
- F1, F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
RA CAPITAL MANAGEMENT, L.P. is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 3 footnotes
Footnote F1
This transaction was executed in multiple trades at prices ranging from $0.35 to $0.3875; the price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and prices at which these transactions, and all other transactions reported in this Form 4, were effected upon request to the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
Footnote F2
These securities include 7,039,613 shares held directly by RA Capital Healthcare Fund, L.P. (the "Fund").
Footnote F3
RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund. The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.